Cite
APA Citation
Strati, P., Coleman, M., Champion, R., Ma, S., Patti, C., Levy, M. Y., Lossos, I. S., Geethakumari, P. R., Lam, S., Calvo, R., Higgins, K., & Budde, L. E. (2022). a phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. British journal of haematology, 199, 76–85. http://access.bl.uk/ark:/81055/vdc_100167019472.0x00005f